Doug Ingram, Sarepta CEO (Sarepta Therapeutics)

Sarep­ta re­veals pos­i­tive re­sults in limb-gir­dle gene ther­a­py tri­al. What does that mean for DMD?

Sarep­ta on Mon­day un­veiled a small batch of pos­i­tive da­ta for one of the gene ther­a­pies it bought out last year, sketch­ing a path to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.